A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Start Date23 Jul 2020

Sponsor / Collaborator

Enterome SA

NCT04116658

/ CompletedPhase 1/2

A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

Start Date13 Jul 2020

Sponsor / Collaborator

Enterome SA

[+1]

100 Clinical Results associated with Tindupepimut

100 Translational Medicine associated with Tindupepimut

100 Patents (Medical) associated with Tindupepimut

News (Medical) associated with Tindupepimut

11 Dec 2024

·www.globenewswire.com

Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite stable metastatic colorectal cancer (mCRC) Paris, France – December 11th, 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced that initial clinical data from the ongoing Phase 1/2 ‘AUDREY’ trial evaluating its innovative OncoMimics™ immunotherapy EO4010 in microsatellite stable metastatic colorectal cancer (CRC), will be presented at the ESMO Immuno-Oncology (IO) Congress, taking place in Geneva, Switzerland, December 11-13, 2024. The AUDREY trial (EOCRC2-22) assesses the safety, tolerability, and preliminary efficacy of EO4010, in combination with nivolumab +/- bevacizumab, in patients with microsatellite stable (MSS), unresectable, and previously treated metastatic colorectal cancer (mCRC) — an indication with limited effective treatment options and poor clinical outcomes. EO4010 includes five OncoMimics™ peptides that mimic tumor-associated antigens (TAAs) highly expressed in colorectal cancer, designed to stimulate CD8+ T cells to target and eliminate tumor cells. Poster presentation details: Abstract #457 Title: EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)Presenting Author: Dr. Romain Cohen, Department of medical oncology, Saint-Antoine hospital, AP-HP, and Assistant Professor of Oncology at Sorbonne University, ParisPoster Session: presentation time December 12, 12:00 PM-13:00 PM CET Key findings: Among the 17 patients evaluated in Cohort 2 of the AUDREY trial, one achieved a partial response, showing a 46% reduction in liver metastases, a 34% reduction in lung metastases, and normalization of carcinoembryonic antigen (CEA) levels. Two additional patients achieved stable disease; one demonstrated a 7% reduction in lung metastases and a marked reduction of tumor biomarkers CEA/CA19-9, while another maintained stable disease beyond 17 weeks. Six patients showed stable disease in target lesions, though with progression in non-target lesions, along with some biomarker reductions. In Cohort 3, which included bevacizumab in addition to EO4010 and nivolumab, three out of five evaluated patients achieved stable disease, with one continuing treatment > 24 weeks (lung met’s +8%, CEA normalized). Immune response analysis showed EO4010-specific CD8+ T cells in 12 out of 13 tested patients, with cross-reactivity to the targeted tumor antigens. Notably, over 80% of these cells were effector memory T cells after five weeks, demonstrating a sustained, targeted immune response. Dr. Romain Cohen, Coordinating Investigator for the AUDREY trial, commented, “These early data highlight EO4010’s potential to induce targeted immune responses and shrinkage of liver metastases in patients with pretreated microsatellite stable metastatic colorectal cancer. We look forward to continued follow-up and further results from the AUDREY trial.” Pierre Bélichard, Chief Executive Officer of Enterome, added, “The presentation of EO4010 data at ESMO IO reflects our dedication to pioneering next-generation immunotherapies for cancers with high unmet needs. These findings support the potential of our OncoMimics™ platform to deliver new options for patients, leveraging multi-target engagement to address tumor heterogeneity and prevent immune escape.” About OncoMimics™OncoMimics™ immunotherapies are designed to activate pre-existing effector memory T cells against bacterial (non-self) peptides that strongly cross-react with corresponding Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer cells. About EO4010EO4010, Enterome’s third clinical-stage OncoMimics™ candidate, combines five microbial-derived peptides that mimic HLA-A2 restricted CD8+ T cell epitopes from five TAAs: BIRC5/survivin, FOXM1, UBE2C (UBCH10), CDC20, and KIF2C (MCAK). It also includes a CD4 helper peptide, Universal Cancer Peptide 2 (UCP2), to bolster immune activation. The BIRC5 and FOXM1 mimic peptides, also used in EO2401, have shown strong immune responses and correlated clinical outcomes in combination with nivolumab +/- bevacizumab for glioblastoma. About AUDREYAUDREY (EOCRC2-22/NCT05589597) is a multicenter, open-label Phase 1/2 trial investigating EO4010 in monotherapy and in combination with nivolumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in 42 patients at centers in Europe and the US. About colorectal cancerColorectal cancer (CRC) is the third most common cancer in men and the second in women, contributing to 10% of all cancers worldwide. It is the fourth most common cause of cancer-related death, with more than 600,000 deaths annually. Despite all efforts regarding surgery and adjuvant therapy, 25% of patients with localized CRC later develop metastases, and around 20% of cases are metastatic at diagnosis. Thus, CRC continues to be a major therapeutic challenge with a considerable number of patients experiencing premature death, fewer than 20% of those diagnosed with recurring/metastatic disease surviving beyond 5 years from diagnosis. Contacts ENTEROME Marie-Laure BouttierChief Corporate Officer+33 (0)1 75 77 27 85communication@enterome.com About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens. The company’s oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies: EO2463, currently in the Phase 2 ‘SIDNEY’ clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy;EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 ‘ROSALIE’ study;EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 ‘AUDREY’ study. Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships. For more information, please visit the company’s website at: www.enterome.com

Clinical ResultImmunotherapyPhase 2

10 Dec 2024

·www.globenewswire.com

Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to 'Watchful Waiting'

46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at the ASH 2024 meeting.Well-tolerated treatment with no severe adverse events.Early CD8+ T cell expansion may predict positive clinical outcomes.Findings support EO2463 as a proactive treatment option for asymptomatic patients who typically go untreated. Paris, France – December 10, 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial evaluating EO2463 in patients with indolent Non Hodgkin Lymphoma. The data were presented in two posters at the 66th American Society of Hematology (ASH) Annual Meeting and Conference by Dr. Villasboas Bisneto, M.D., hematologist and oncologist at Mayo Clinic, and Dr. Stephen Smith, M.D., hematologist and oncologist at Fred Hutchinson Cancer Center. Enterome is also holding a webinar on December 12, 2024 for external audiences in order to run through the data sets. See details at the end of this release. The Phase 1/2 SIDNEY trial (EONHL1-20) investigates EO2463, an off-the-shelf immunotherapy targeting four B cell antigens and based on Enterome’s OncoMimic™ peptides, in patients with frequent forms of indolent Non-Hodgkin Lymphoma. In Cohort 2 of the SIDNEY trial, patients with newly diagnosed, asymptomatic follicular lymphoma, received EO2463 monotherapy as an alternative to the standard “watch-and-wait” approach. With most patients still on study treatment, an objective response rate of 46% has been observed in the first 13 patients, including 15% complete responses and 31% partial responses. Consistent with observations from the safety lead-in cohort, the treatment was well tolerated, with no severe adverse events, suggesting EO2463 may offer a safe treatment option for patients with early-stage disease. A biomarker analysis was conducted in Cohort 1 (EO2463 in monotherapy and in combination with lenalidomide/rituximab, in patients with relapsed/refractory disease) to explore whether early CD8+ T cell expansion in response to EO2463 administration could serve as a predictor of later clinical benefit. The current assessment indicates that the biomarker as applied (measuring fast expansion of EO2463 specific CD8 T cells) can predict for clinical response, both for EO2463 monotherapy, and for EO2463 in combination with lenalidomide + rituximab. Jan Fagerberg, Chief Medical Officer of Enterome, commented, “These new data provide encouraging indications that EO2463 can safely induce meaningful responses in patients with newly diagnosed follicular lymphoma typically managed with observation alone, addressing an important unmet need. Additionally, our biomarker findings open up possibilities for precision immunotherapy by identifying patients most likely to benefit early in their treatment course.” Pierre Bélichard, CEO of Enterome, added, “These promising results from Cohort 2 in the SIDNEY trial mark an important step in our commitment to providing early therapeutic options for patients who would usually not receive immediate treatment due to the absence of safe and effective therapies. We look forward to advancing EO2463 through the SIDNEY trial and to expanding our work with OncoMimics™ immunotherapies in other blood cancer types.” Details of the poster presentations: Abstract #1616 Title: EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/RituximabPresenting Author: Jose Caetano (JC) Villasboas, MD Mayo ClinicSession: 622. Lymphomas: Translational – Non-Genetic: Poster I Abstract #4395 Title: EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/SIDNEY StudyPresenting Author: Dr. Stephen Smith, M.D., UW Medicine, Fred Hutchinson Cancer Research CenterSession: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III About EONHL1-20/SIDNEY: SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as a monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with iNHL. The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). For more information on the study, visit www.Clinicaltrials.gov, reference: NCT04669171. About EO2463: EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. Details of the webinar, please register at enterome@vigoconsulting.com to attend. Date: 12 December 2024 Time: 7.30am-8.30am PT / 9.30am-10.30am Central US time / 3.30pm-4.30pm UK / 4.30pm-5.30pm CET Presenters: Jose Caetano (JC) Villasboas, MD Mayo Clinic Pierre Belichard PhD, CEO, Enterome Laurent Chene PhD, Head of Drug Discovery, Enterome Jan Fagerberg, MD, PhD, CMO Enterome Registration link: HERE (https://storm-virtual-uk.zoom.us/webinar/register/WN_jTBLmm7ZRBK6KLvtG3I6Lw) Webinar ID 822 5290 4200 Contacts ENTEROMEMEDIA RELATIONSMarie-Laure BouttierChief Corporate Officer+33 (0)1 75 77 27 85communication@enterome.comVigo ConsultingMelanie Toyne-Sewell / Rozi Morris+44 207 390 0237 / 0231enterome@vigoconsulting.com About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens. The company’s oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies: EO2463, currently in the Phase 2 ‘SIDNEY’ clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy;EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 ‘ROSALIE’ study;EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 ‘AUDREY’ study. Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships. For more information, please visit the company’s website at: www.enterome.com

ImmunotherapyClinical ResultPhase 1

13 Nov 2024

·www.businesswire.com

Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463

PARIS--( BUSINESS WIRE )-- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform , will be holding a webinar to run through new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of EO2463, for the treatment of patients with either newly diagnosed, previously untreated follicular lymphoma (FL) [EO2463 monotherapy], or FL and marginal zone lymphoma relapsed/refractory disease [EO2463 in combination with lenalidomide/rituximab]. The data is being presented in two posters at the 66 th American Society of Hematology (ASH) Annual Meeting and Conference by Jose Caetano (JC) Villasboas Bisneto, MD, PhD, principal study investigator at the Mayo Clinic, and Stephen Smith, MD, hematologist and medical oncologist at the Fred Hutchinson Cancer Center. Poster details Abstract #1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab Abstract #4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/SIDNEY Study Webinar details are as follows: Date : 12 December 2024 Time : 9.30am-10.35am PT / 12.30pm-1.35pm ET / 5.30pm-6.35pm UK / 6.30pm-7.35pm CET Presenters : Pierre Belichard PhD, CEO, Enterome Laurent Chene PhD, Head of Drug Discovery, Enterome Jose Caetano (JC) Villasboas Bisneto, MD, PhD, Mayo Clinic Jan Fagerberg, MD, PhD, CMO of Enterome will also be present for the Q&A session following the presentation. To attend, please register your details at enterome@vigoconsulting.com . Questions can be submitted at any time during the presentation. Background About EONHL1-20/SIDNEY: SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as a monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with iNHL. The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). For more information on the study, visit www.Clinicaltrials.gov , reference: NCT04669171 . About EO2463: EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens. The company’s oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies: EO2463, currently in the Phase 2 ‘SIDNEY’ clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy; EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 ‘ROSALIE’ study; EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 ‘AUDREY’ study. Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships. For more information, visit: www.enterome.com

ImmunotherapyPhase 2Clinical ResultASHPhase 1

100 Deals associated with Tindupepimut

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adrenal Gland Neoplasms	Phase 2	-	Enterome SA	15 Jun 2023
Adrenocortical Carcinoma	Phase 2	United States	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Denmark	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	France	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Germany	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Italy	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Netherlands	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Spain	Enterome SA	23 Jul 2020
Adrenocortical Carcinoma	Phase 2	Sweden	Enterome SA	23 Jul 2020
Pheochromocytoma	Phase 2	United States	Enterome SA	23 Jul 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04116658 (ROSALIE \| EOGBM1-18, SNO2023) Manual	Phase 1/2	Glioblastoma	-	EO2401 + Nivolumab+ bevacizumab (C1a (Ex2→EN; option for symptom directed low-dose bevacizumab [sLDB; 5mg/kg, q2weeks] as anti-edema treatment))	clsyssmvhk(aeicdlhfsw) = wswyupihfv sahybrlpre (vazfuxprwr ) View more	Positive	10 Nov 2023
				EO2401 + Nivolumab (C2a/1 (EN))	clsyssmvhk(aeicdlhfsw) = piryzdqiwa sahybrlpre (vazfuxprwr ) View more
NCT04187404 (EOADR1-19/SPENCER, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Adrenocortical Carcinoma \| Paraganglioma \| Pheochromocytoma	-	EO2401 + nivolumab (C2a；ACC 2nd/3rd line)	faezgbhyvw(ruajsorcns) = cowtshbhvs ipxlobpntb (rqhxkovffi ) View more	Positive	22 Oct 2023
				EO2401 + nivolumab (C2b；ACC 1st line)	faezgbhyvw(ruajsorcns) = vknisyejit ipxlobpntb (rqhxkovffi ) View more
NCT04116658 (EOGBM1-18/ROSALIE, SITC2022)	Phase 1/2	Recurrent Glioblastoma	40	EO2401 + Nivolumab	ygvkotalgk(aasghiapld) = limited to local administration site reactions (45% of patients; events 70% Grade 1, 26% Grade 2, and 4% Grade 3) buywwlyfpx (lqjslsyycv ) View more	Positive	07 Nov 2022
				EO2401 + Nivolumab + Bevacizumab
NCT04116658 (EOGBM1-18/ROSALIE, SITC2022)	Phase 1/2	-	29	EO2401 with nivolumab (EN)	wcmczwenyy(pydfdrxliw) = dvflbjbltn fzimzgxton (ubpnskgfem )	Positive	07 Nov 2022
				EN with bevacizumab	wcmczwenyy(pydfdrxliw) = dlxgnlvtwa fzimzgxton (ubpnskgfem )
NCT04187404 (SPENCER \| EOADR1-19, Corporate Publications) Manual	Phase 1/2	Adrenocortical Carcinoma \| Pheochromocytoma	46	Nivolumab+EO2401 (ACC)	nmepchlues(pcnkkzxgho) = otjqlgbjpp npbdplldcb (sawcbtmabo, 1.8 - 2.3) View more	Positive	12 Sep 2022
				Nivolumab+EO2401 (MPP)	nmepchlues(pcnkkzxgho) = wedunnezlk npbdplldcb (sawcbtmabo, 1.9 - NE) View more
NCT04187404 (SPENCER, ESMO2022)	Phase 1/2	Paraganglioma \| Pheochromocytoma	-	EO2401 + nivolumab	gcoqnxhevp(upwuqshwfg) = gxagdlptxw ekdbugdkwc (tqoriksczt ) View more	-	12 Sep 2022
NCT04116658 (ROSALIE, ESMO2022)	Phase 1/2	Recurrent Glioblastoma	100	EO	osaxxbbaqj(sbgtambgyb) = raxjnredic daaznstquh (uswbeslxhj ) View more	-	10 Sep 2022
				EO with nivolumab	osaxxbbaqj(sbgtambgyb) = dxowjcbibe daaznstquh (uswbeslxhj ) View more
NCT04116658 (EO2401, EANO2022)	Phase 1/2	Recurrent Glioblastoma HLA-A2 \| IL13Rα2 \| BIRC5 ... View more	40	EO2401	cdovkjycle(rdfmeevjxf) = limited to local administration site reactions (48%; all grade 1-2) mqpnbxbrpx (npkqwemjdc ) View more	Positive	05 Sep 2022
				EO2401 + Nivolumab
NCT04116658 (ROSALIE, ASCO2022) Manual	Phase 1/2	Recurrent Glioblastoma	40	EO2401 + nivolumab	mmlquiozxl(ajsmjngzpp) = jdjokupssj tzsxpbqhhy (mdiblrhdtj ) View more	Positive	02 Jun 2022
				EO2401 + nivolumab + bevacizumab	mmlquiozxl(ajsmjngzpp) = ydnfcuqmbn tzsxpbqhhy (mdiblrhdtj ) View more
NCT04187404 (SPENCER, ASCO2022) Manual	Phase 1/2	Adrenocortical Carcinoma	33	nivolumab+EO2401	qelixqnaab(gzxrrbvysu) = fskhgmttra qfywuepqgz (afruqqngkx, 0.4 - 7.6+) View more	Positive	02 Jun 2022
				nivolumab+EO2401 ( pts with metastatic ACC, with prior systemic therapy)	ymrqkpeemd(xoofxagpcu) = wcojzzyqad vtktdrldrv (ksdjpmhruc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tindupepimut

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation